GlassScriptPhysician profile
Jonathan V Henzel
NPI 1114597721
$3,318.69
in general payments reported to CMS, 2019-2025
21 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.77 · 2022: $780 · 2023: $124 · 2024: $833 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,447 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,446.54 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $774.72 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $311.19 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $309.81 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $265.42 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $223.87 | 2022 | |
| Abbvie INC. | $217.50 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $206.41 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $198.15 | 2024-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $178.48 | 2024-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $155.93 | 2022-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $89.46 | 2023-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $80.14 | 2025 | Qelbree |
| Corium, LLC | $77.83 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $57.45 | 2024-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $36.25 | 2025 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $31.93 | 2023 | |
| Neuronetics, INC. | $30.86 | 2024 | Neurostar Tms Therapy System |
| Ironshore Pharmaceuticals INC. | $26.75 | 2024 | |
| Indivior INC. | $16.35 | 2022 | |
| Eisai INC. | $15.13 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.06 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Henzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.